50
Participants
Start Date
September 29, 2021
Primary Completion Date
January 1, 2025
Study Completion Date
October 1, 2026
Patients receiving neoadjuvant therapy before radical nephrectomy
Chemotherapy using either a combination of Gemcitabine/Cisplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736) or Chemotherapy with either Gemcitibine/Carboplatin and neoadjuvant immunotherapy therapy with Durvalumab (MEDI 4736)
RECRUITING
Institut Paoli Calmette, Marseille
RECRUITING
Iuct Oncopole, Toulouse
RECRUITING
Centre Eugène Marquis, Rennes
RECRUITING
Centre hospitalier Lyon Sud, Pierre-Bénite
RECRUITING
Hôpital Saint Louis, Paris
RECRUITING
Hôpital Européen Georges Pompidou, Paris
RECRUITING
Hôpital Bichat-Claude Bernard, Paris
RECRUITING
Hôpital Foch, Suresnes
RECRUITING
Hôpital Pitié Salpétrière, Paris
Pitié-Salpêtrière Hospital
OTHER
Hôpital Bichat-Claude Bernard, 75018 Paris
UNKNOWN
Hopital Foch 92151 Suresnes
UNKNOWN
Institut Paoli-Calmettes
OTHER
European Georges Pompidou Hospital
OTHER
Saint-Louis Hospital, Paris, France
OTHER
Centre Hospitalier Lyon Sud
OTHER
Center Eugene Marquis
OTHER
IUCT ONCOPOLE
UNKNOWN
Centre Hospitalier Universitaire de Nīmes
OTHER